US Stock MarketDetailed Quotes

Hemab Therapeutics Holdings (COAG)

Watchlist
  • 26.940
  • +1.390+5.44%
Close Jun 11 16:00 ET
  • 26.940
  • 0.0000.00%
Post 16:10 ET
1.26BMarket Cap-16.70P/E (TTM)

Hemab Therapeutics Holdings (COAG) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
Total revenue
0
0
0
0
Operating revenue
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
42.58%23.61M
39.17%70.12M
16.56M
50.38M
Selling and administrative expenses
68.81%4.15M
16.90%10.49M
--2.46M
--8.97M
-General and administrative expense
68.81%4.15M
16.90%10.49M
--2.46M
--8.97M
Research and development costs
38.01%19.46M
44.00%59.63M
--14.1M
--41.41M
Operating profit
-42.58%-23.61M
-39.17%-70.12M
-16.56M
-50.38M
Net non-operating interest income expense
157.72%1.22M
-47.22%1.97M
473K
3.74M
Non-operating interest income
157.72%1.22M
-47.22%1.97M
--473K
--3.74M
Other net income (expense)
-147.72%-282K
313.15%4.01M
591K
-1.88M
Other non- operating income (expenses)
-147.72%-282K
313.15%4.01M
--591K
---1.88M
Income before tax
-46.33%-22.68M
-32.19%-64.14M
-15.5M
-48.52M
Income tax
106.32%12K
-222.70%-227K
-190K
185K
Net income
-48.22%-22.69M
-31.22%-63.91M
-15.31M
-48.71M
Net income continuous Operations
-48.22%-22.69M
-31.22%-63.91M
---15.31M
---48.71M
Minority interest income
Net income attributable to the parent company
-48.22%-22.69M
-31.22%-63.91M
-15.31M
-48.71M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-48.22%-22.69M
-31.22%-63.91M
-15.31M
-48.71M
Basic earnings per share
-48.21%-23.98
-31.28%-2.33
-16.18
-1.7748
Diluted earnings per share
-48.21%-23.98
-31.28%-2.33
-16.18
-1.7748
Dividend per share
Currency Unit
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024
Total revenue 0000
Operating revenue --0--0--0--0
Cost of revenue
Gross profit
Operating expense 42.58%23.61M39.17%70.12M16.56M50.38M
Selling and administrative expenses 68.81%4.15M16.90%10.49M--2.46M--8.97M
-General and administrative expense 68.81%4.15M16.90%10.49M--2.46M--8.97M
Research and development costs 38.01%19.46M44.00%59.63M--14.1M--41.41M
Operating profit -42.58%-23.61M-39.17%-70.12M-16.56M-50.38M
Net non-operating interest income expense 157.72%1.22M-47.22%1.97M473K3.74M
Non-operating interest income 157.72%1.22M-47.22%1.97M--473K--3.74M
Other net income (expense) -147.72%-282K313.15%4.01M591K-1.88M
Other non- operating income (expenses) -147.72%-282K313.15%4.01M--591K---1.88M
Income before tax -46.33%-22.68M-32.19%-64.14M-15.5M-48.52M
Income tax 106.32%12K-222.70%-227K-190K185K
Net income -48.22%-22.69M-31.22%-63.91M-15.31M-48.71M
Net income continuous Operations -48.22%-22.69M-31.22%-63.91M---15.31M---48.71M
Minority interest income
Net income attributable to the parent company -48.22%-22.69M-31.22%-63.91M-15.31M-48.71M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -48.22%-22.69M-31.22%-63.91M-15.31M-48.71M
Basic earnings per share -48.21%-23.98-31.28%-2.33-16.18-1.7748
Diluted earnings per share -48.21%-23.98-31.28%-2.33-16.18-1.7748
Dividend per share
Currency Unit USDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAP
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
The U.S.-Iran conflict shows signs of easing. On the 11th, Eastern Time, Trump revealed that the United States and Iran are expected to reac Show More